Literature DB >> 11076534

Stoichiometry of cyclin A-cyclin-dependent kinase 2 inhibition by p21Cip1/Waf1.

J N Adkins1, K J Lumb.   

Abstract

Progression through the eukaryotic cell cycle is regulated by phosphorylation, which is catalyzed by cyclin-dependent kinases. Cyclin-dependent kinases are regulated through several mechanisms, including negative regulation by p21 (variously called CAP20, Cip1, Sdi1, and WAF1). It has been proposed that multiple p21 molecules are required to inhibit cyclin-dependent kinases, such that p21 acts as a sensitive buffer of cyclin-dependent kinase activity or as an assembly factor for the complexes formed by the cyclins and cyclin-dependent kinases. Using purified, full-length proteins of known concentration (determined by absorbance) and cyclin A-Cdk2 of known activity (calibrated with staurosporine), we find that a 1:1 molar ratio of p21 to cyclin A-Cdk2 is able to inhibit Cdk2 activity both in the binary cyclin A-Cdk2 complex and in the presence of proliferating cell nuclear antigen (PCNA). Our results indicate that the mechanism of p21 inhibition of cyclin A-Cdk2 does not involve multiple molecules of bound p21.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11076534     DOI: 10.1021/bi001524e

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  3 in total

1.  Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding.

Authors:  Lisa Héron-Milhavet; Celine Franckhauser; Vanessa Rana; Cyril Berthenet; Daniel Fisher; Brian A Hemmings; Anne Fernandez; Ned J C Lamb
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

2.  The Regulation of Multiple p53 Stress Responses is Mediated through MDM2.

Authors:  Wenwei Hu; Zhaohui Feng; Arnold J Levine
Journal:  Genes Cancer       Date:  2012-03

3.  Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents.

Authors:  G He; J Kuang; J Koomen; R Kobayashi; A R Khokhar; Z H Siddik
Journal:  Br J Cancer       Date:  2013-10-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.